Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial

BACKGROUND: Triple antimalarial combination therapies combine potent and rapidly cleared artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly eliminated partner drugs to reduce the risk of resistance. We aimed to assess the safety, tolerability, and efficacy of arter...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamaluba, Mainga, van der Pluijm, Rob W, Weya, Joseph, Njuguna, Patricia, Ngama, Mwanajuma, Kalume, Peter, Mwambingu, Gabriel, Ngetsa, Caroline, Wambua, Juliana, Boga, Mwanamvua, Mturi, Neema, Lal, Altaf A, Khuroo, Arshad, Taylor, Walter R J, Gonçalves, Sónia, Miotto, Olivo, Dhorda, Mehul, Mutinda, Brian, Mukaka, Mavuto, Waithira, Naomi, Hoglund, Richard M, Imwong, Mallika, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, Bejon, Philip, Dondorp, Arjen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461080/
https://www.ncbi.nlm.nih.gov/pubmed/34111412
http://dx.doi.org/10.1016/S1473-3099(20)30929-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461080/
https://www.ncbi.nlm.nih.gov/pubmed/34111412
http://dx.doi.org/10.1016/S1473-3099(20)30929-4

Ejemplares similares